RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$176.93
−1.00%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$178.30
From 52W high−9.07%
Volume1.06M
Market cap$11.23B
P/E (TTM)239.1x
P/S (TTM)14.3x
Div yield—
Key dataOct 23, 2026
Open
$178.30
From 52W high
−9.07%
Volume
1.06M
Market cap
$11.23B
ValuationView details →
P/E (Fwd)
72.8x
EV/EBITDA
63.6x
P/E (TTM)
239.1x
RSI (14)
48.5
MomentumView details →
1D Return
−1.00%
YTD Return
+7.27%
SummaryUpdated Jun 1, 2026
Repligen Corporation (NASDAQ:RGEN) is a leading bioprocessing technology company founded in 1981 and headquartered in Waltham, Massachusetts. The company went public in 1986 and has evolved from its origins as a biotechnology research company into a specialized provider of critical tools and technologies used in the manufacturing of biological drugs. Repligen serves the global biopharmaceutical industry by supplying essential equipment, consumables, and systems that enable the production of life-saving biologics including monoclonal antibodies, vaccines, cell and gene therapies, and other advanced therapeutic modalities.
Similar companies
Latest newsMore news →
Repligen announced that it will report its third-quarter 2026 financial results on October 27, 2026.12d agoRepligen Corporation completed its previously announced acquisition of BioLife Solutions, Inc., a developer and supplier of cell processing tools and services for the cell and gene therapy market.19d ago